Talaris initiates FREEDOM-1 clinical trial for FCR001 in LDKT recipients
Talaris Therapeutics has initiated the phase 3 FREEDOM-1 clinical trial to evaluate its investigational, allogeneic cell therapy FCR001 in living donor kidney transplant (LDKT) recipients. ... Read More
Cell therapy company Talaris Therapeutics raises $100m in Series A round
Talaris Therapeutics (formerly Regenerex) has raised $100 million in a Series A financing round to advance its allogeneic cell therapy FCR001 into phase 3 development ... Read More